上QQ阅读APP看书，第一时间看更新
参考文献
1.Nelson JS，Wells JR，Baker JA，et al. How does c-view image quality compare with conventional 2D FFDM? [J]. Med Phys，2016，43（5）：2538.
2.Mariscotti G，Durando M，Houssami N，et al. Comparison of synthetic mammography，reconstructed from digital breast tomosynthesis，and digital mammography：evaluation of lesion conspicuity and BI-RADS assessment categories.[J]. Breast Cancer Res Treat，2017，166（3）：765-773.
3.李志，钱明理，汪登斌，等．乳腺专用磁共振成像、乳腺X线摄影及超声检查对乳腺癌诊断价值的对照研究[J]．临床放射学杂志，2012，31（6）：794-799.
4.赵永霞，秦维昌．数字乳腺X线摄影的现状与进展[J]．中华放射学杂志，2007，41（12）：1421-1424.
5.宁瑞平，王延林，陈巨坤．1470例乳腺X线摄影技术探讨 [J]．中国医学影像学杂志，2003，11（4）：310-311.
6.崔宝军，陈步东，胡志海，等．全数字乳腺X线摄影规范化操作探讨 [J]．临床和实验医学杂志，2011，10（9）：684-686.
7.Alakhras M，Bourne R，Rickard M，et al. Digital tomosynthesis：a new future for breast imaging[J]. Clin Radiol，2013，68（5）：e225-236.
8.Rose SL，Tidwell AL，Bujnoch LJ，et al. Implementation of breast tomosynthesis in a routine screening practice：an observational study[J]. AJR Am J Roentgenol，2013，200（6）：1401-1408.
9.Svahn TM，Houssami N，Sechopoulos I，et al. Review of radiation dose estimates in digital breast tomosynthesis relative to those in two-view full-field digital mammography[J].Breast，2015，24（2）：93-99.
10.Thomassin-Naggara I，Perrot N，Dechoux S，et al. Added value of one-view breast tomosynthesis combined with digital mammography according to reader experience[J]. Eur J Radiol，2015，84（2）：235-241.
11.Elizalde A，Pina L，Etxano J，et al. Additional US or DBT after digital mammography：which one is the best combination[J].Acta Radiol，2014，57（1）：13-18.
12.Bouwman RW，Diaz O，van Engen RE，et al. Phantoms for quality control procedures in digital breast tomosynthesis：dose assessment[J]. Phys Med Biol，2013，58（13）：4423-4438.
13.Mercado CL. BI-RADS update[J]. Radiol Clin North Am，2014，52（3）：481-487.
14.Leithner D，Wengert GJ，Helbich TH，et al. Clinical role of breast MRI now and going forward[J]. Clin Radiol，2018，73（8）：700-714.
15.Alakhras M，Bourne R，Rickard M，et al. Digital tomosynthesis：a new future for breast imaging[J]. Clin Radiol，2013，68（5）：225-236.
16.Mall S，Lewis S，Brennan P，et al. The role of digital breast tomosynthesis in the breast assessment clinic：a review[J]. J Med Radiat Sci，2017，64（3）：203-211.
17.Hooley RJ，Durand MA，Philpotts LE. Advances in digital breast tomosynthesis[J]. AJR Am J Roentgenol，2017，208（2）：256-266.
18.Mercado CL. BI-RADS update[J]. Radiol Clin North Am，2014，52（3）：481-487.
19.Feng SS，Sechopoulos I. Clinical digital breast tomosynthesis system：dosimetric characterization[J]. Radiology，2012，263（1）：35-42.
20.Sechopoulos I. A review of breast tomosynthesis. Part I. The image acquisition process[J]. Med Phys，2013，40（1）：014301.
21.Cavagnetto F，Taccini G，Rosasco R，et al. ‘In vivo’ average glandular dose evaluation：one-to-one comparison between digital breast tomosynthesis and full-field digital mammography[J]. Radiat Prot Dosimetry，2013，157（1）：53-61.
22.Wallis MG，Moa E，Zanca F，et al. Two-view and singleview tomosynthesis versus full-field digital mammography：high-resolution X-ray imaging observer study[J]. Radiology，2012，262（3）：788-796.
23.Helvie MA. Digital mammography imaging：breast tomosynthesis and advanced applications[J]. Radiol Clin North Am，2010，48（5）：917-929.
24.Bernardi D，Ciatto S，Pellegrini M，et al. Application of breast tomosynthesis in screening：incremental effect on mammography acquisition and reading time[J]. Br J Radiol，2012，85（1020）：e1174-1178.
25.Gur D，Klym AH，King JL，et al. Impact of the New Density Reporting Laws：Radiologist Perceptions and Actual Behavior[J]. Acad Radiol，2015，22（6）：679-683.
26.Kul S，Oguz S，Eyuboglu I，et al. Can unenhanced breast MRI be used to decrease negative biopsy rates[J]. Diagn Interv Radiol，2015，21（4）：287-292.
27.Elverici E，Barca AN，Aktas H，et al. Nonpalpable BI-RADS 4 breast lesions：sonographic findings and pathology correlation[J]. Diagn Interv Radiol，2015，21（3）：189-194.
28.Kim MY，Choi N，Yang JH，et al. Background parenchymal enhancement on breast MRI and mammographic breast density：correlation with tumour characteristics[J]. Clin Radiol，2015，70（7）：706-710.
29.Raikhlin A，Curpen B，Warner E，et al. Breast MRI as an adjunct to mammography for breast cancer screening in high-risk patients：retrospective review[J]. AJR Am J Roentgenol，2015，204（4）：889-897.
30.Scoggins ME，Fox PS，Kuerer HM，et al. Correlation between sonographic findings and clinicopathologic and biologic features of pure ductal carcinoma in situ in 691 patients[J].AJR Am J Roentgenol，2015，204（4）：878-888.
31.Kharuzhyk SA，Shimanets SV，Karman AV，et al. Use of BI-RADS to interpret magnetic resonance mammography for breast cancer[J]. Vestn Rentgenol Radiol，2014（4）：46-59.
32.Fallenberg EM，Dromain C，Diekmann F，et al. Contrastenhanced spectral mammography versus MRI：Initial results in the detection of breast cancer and assessment of tumour size[J]. Eur Radiol，2014，24（1）：256-264.
33.Fallenberg EM，Dromain C，Diekmann F，et al. Contrastenhanced spectral mammography：Does mammography provide additional clinical benefits or can some radiation exposure be avoided[J]. Breast Cancer Res Treat，2014，146（2）：371-381.
34.Lobbes MB，Lalji UC，Nelemans PJ，et al. The quality of tumor size assessment by contrast-enhanced spectral mammography and the benefit of additional breast MRI[J]. J Cancer，2015，6（2）：144-150.
35.Cheung YC，Lin YC，Wan YL，et al. Diagnostic performance of dual-energy contrast-enhanced subtracted mammography in dense breasts compared to mammography alone：interobserver blind-reading analysis[J]. Eur Radiol，2014，24（10）：2394-2403.
36.Luczynska E，Heinze-Paluchowska S，Dyczek S，et al. Contrast-enhanced spectral mammography：comparison with conventional mammography and histopathology in 152 women[J]. Korean J Radiol，2014，15（6）：689-696.
37.Jochelson MS，Dershaw DD，Sung JS，et al. Bilateral contrast-enhanced dual-energy digital mammography：feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma[J]. Radiology，2013，266（3）：743-751.
38.Mohamed KR，Hussien HM，Wessam R，et al. Contrastenhanced spectral mammography：Impact of the qualitative morphology descriptors on the diagnosis of breast lesions[J].Eur J Radiol，2015，84（6）：1049-1055.
39.Daniaux M，De Zordo T，Santner W，et al. Dual-energy contrast-enhanced spectral mammography（CESM）[J].Arch Gynecol Obstet，2015，292（4）：739-747.
40.Vachon CM，Pankratz VS，Scott CG，et al. The contributions of breast density and common genetic variation to breast cancer risk[J]. J Natl Cancer Inst，2015，107（5）：397.
41.中国医师协会超声医师分会．中国浅表器官超声检查指南[M]．北京：人民卫生出版社，2017：142-149.
42.张建兴．乳腺超声诊断学[M]．北京：人民卫生出版社，2012：9-13.
43.姜玉新，王志刚．医学超声影像学[M]．北京：人民卫生出版社，2013，396-397.
44.Balleyguier C，Ciolovan L，Ammari S，et al. Breast elastography：the technical process and its applications[J]. Diagn Interv Imaging，2013，94（5）：503-513.
45.Gkali CA，Chalazonitis AN，Feida E，et al. Breast Elastography：How We Do It[J]. Ultrasound Q，2015，31（4）：255-261.
46.欧冰，吴嘉仪，周薪传，等．多中心研究：弹性应变率比值对弹性评分法评估乳腺病灶良恶性的辅助价值探讨[J]．中华超声影像学杂志，2017，26（10）：867-871.
47.Li Q，Hu M，Chen Z，et al. Meta-Analysis：Contrast-Enhanced Ultrasound Versus Conventional Ultrasound for Differentiation of Benign and Malignant Breast Lesions[J].Ultrasound Med Biol，2018，44（5）：919-929.
48.朱庆莉，姜玉新．超声造影在乳腺肿瘤诊断中的应用[J]．中国医学影像技术，2003，19（10）：1404-1406.
49.中华医学会放射学分会乳腺专业委员会专家组．乳腺磁共振检查及诊断规范专家共识[J]．肿瘤影像，2017，26（4）：241-249.
50.中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范（2017年版）[J]．中国癌症杂志，2017，27（9）：695-760.
51.Miller BT，Abbott AM，Tuttle TM. The influence of preoperative MRI on breast cancer treatment[J]. Ann Surg Oncol，2012，19（2）：536-540.
52.Jochelson MS，Lebron L，Jacobs SS，et al. Detection of Internal Mammary Adenopathy in Patients with Breast Cancer by PET/CT and MRI[J]. AJR Am J Roentgenol，2015，205（4）：899-904.
53.Uematsu T，Kasami M，Watanabe J. Background enhancement of mammary glandular tissue on breast dynamic MRI：Imaging features and effect on assessment of breast cancer extent[J]. Breast cancer，2012，19（3）：259-265.
54.Kuhl C，Weigel S，Schrading S，et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer；the EVA trial[J]. J Clin Oncol，2010，28（9）：1450-1457.
55.Buck A，Wahl A，Eicher U，et al. Combined morphological and functional imaging with FDG PET/CT for restaging breast cancer：impact on patient management[J]. J Nucl Med，2003，44S：78-84.
56.Kalinyak JE，Berg WA，Schilling K，et al. Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT[J]. Eur J Nucl Med Mol Imaging，2014，41：260-275.
57.D'Souza MM1，Jaimini A，Tripathi M，et al. F-18 FDG and C-11 methionine PET/CT in intracranial dural metastases[J].Clinical Nuclear Medicine，2012，37（2）：206-209.
58.Tamura K，Kurihara H，Yonemori K，et al. 64Cu-DOTATrastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer[J]. J Nucl Med，2013；54：1869-1875.
59.Kurihara H，Hamada A，Yoshida M，et al. 64Cu-DOTA-trastuzumab PET imaging and HER2-specificity of brain metastases in HER2-positive breast cancer patients[J]. Ejnmmi Res，2015，5：8.
60.Quon A，Gambhir SS. FDG-PET and beyond：molecular breast cancer imaging[J]. J Clin Oncol，2005，23：1664-1673.
61.Pace L，Nicolai E，Luongo A，et al. Comparison of wholebody PET/CT and PET/MRI in breast cancer patients：lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues[J]. Eur J Radiol，2014，83：289-296.
62.Buck A，Schirrmeister H，Kuhn T，et al. FDG uptake in breast cancer：correlation with biological and clinical prognostic parameters[J]. Eur J Nucl Med Mol Imaging，2002，29：1317-1323.
63.Salskov A，Tammisetti VS，Grierson J，et al. FLT：measuring tumor cell proliferation in vivo with positron emission tomography and 3-deoxy-3-[18F]fluorothymidine[J]. Semin Nucl Med，2007，37：429-439.
64.Gemignani ML，Patil S，Seshan VE，et al. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer[J]. J Nucl Med，2013，54：1697-1702.
65.Mortimer JE，Bading JR，Colcher DM，et al. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using（64）CuDOTA-trastuzumab PET[J]. J Nucl Med，2014，55：23-29.
66.Gaykema SB，Brouwers AH，Lub-de Hooge MN，et al.89Zr-bevacizumab PET imaging in primary breast cancer[J].J Nucl Med，2013，54：1014-1018.
67.Chen X，Park R，Tohme M，et al. MicroPET and autoradiographic imaging of breast cancer av-Integrin Expression Using 18F- and 64Cu-Labeled RGD Peptide[J]. Bioconjug Chem，2004，15：41-49.
68.叶兆祥，伍尧泮，刘佩芳．锥光束乳腺CT诊断图谱[M]．北京：人民卫生出版社，2017.
69.Michell MJ，Iqbal A，Wasan RK，et al. A comparison of the accuracy of film-screen mammography，full-field digital mammography，and digital breast tomosynthesis[J]. Clin Radiol，2012，67（10）：976-981.
70.Hooley RJ，Durand MA，Philpotts LE，et al. Advances in Digital Breast Tomosynthesis. [J]. AJR Am J Roentgenol，2017，208（2）：256-266.
71.Gilbert FJ，Tucker L，Young KC，et al. Digital breast tomosynthesis（DBT）：a review of the evidence for use as a screening tool[J]. Clin Radiol，2016，71（2）：141-150.
72.王欣，杨剑敏．乳腺癌的现代诊断方法及其评价[J]．中华肿瘤防治杂志，2006，13（3）：31-35.
73.Skaane P，Young K，Skjennald A，et al. Population-based mammography screening：comparison of screen-film and full-field digital mammography with soft-copy reading-OsloI study[J]. Radiology，2003，229：877-884.
74.Li L，Roth R，Germaine P，et al. Contrast-enhanced spectral mammography（CESM）versus breast magnetic resonance imaging（MRI）：A retrospective comparison in 66 breast lesions[J]. Diagn Interv Imaging，2017，98（2）：113-123.
75.Patel BK，Lobbes MBI，Lewin J. Contrast Enhanced Spectral Mammography：A Review[J]. Semin Ultrasound CT MR，2018，39（1）：70-79.
76.Fallenberg EM，Schmitzberger FF，Amer H，et al. Contrastenhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation[J].Eur Radiol，2017，27（7）：2752-2764.